<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0"><channel><title>Yahoo! Finance: AZN.L News</title><copyright>Copyright (c) 2013 Yahoo! Inc. All rights reserved.</copyright><link>http://finance.yahoo.com/q/h?s=azn.l</link><description>Latest Financial News for ASTRAZENECA</description><language>en-US</language><lastBuildDate>Wed, 19 Jun 2013 21:11:53 GMT</lastBuildDate><image><url>http://l.yimg.com/a/i/brand/purplelogo/uh/us/fin.gif</url><title>Yahoo! Finance: AZN.L News</title><link>http://finance.yahoo.com/q/h?s=azn.l</link><width>144</width><height>45</height></image><item><title>Innovation: Pharmaceutical groups become victims of their own success</title><link>http://us.rd.yahoo.com/finance/external/ft/rss/SIG=129qsghmp/*http://www.ft.com/cms/s/cc4bf528-c953-11e2-bb56-00144feab7de,s01=1.html</link><description>[at Financial Times] - Every few months, the Hever Group - an informal gathering of the heads of research and development at the large pharmaceutical companies - comes together for what Jan Lundberg of Eli Lilly jokes is a collective ...</description><guid isPermaLink="false">yahoo_finance/4287755846</guid><pubDate>Wed, 19 Jun 2013 21:11:53 GMT</pubDate></item><item><title>Astra, Bristol diabetes drug disappoints in key test</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://uk.finance.yahoo.com/news/astrazeneca-bristol-diabetes-drug-disappoints-065504442.html</link><description></description><guid isPermaLink="false">yahoo_finance/371857374</guid><pubDate>Wed, 19 Jun 2013 16:09:02 GMT</pubDate></item><item><title>Study: no new benefits for diabetes drug Onglyza</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/study-no-benefits-diabetes-drug-151601564--finance.html</link><description></description><guid isPermaLink="false">yahoo_finance/1859186643</guid><pubDate>Wed, 19 Jun 2013 15:16:01 GMT</pubDate></item><item><title>Study: no new benefits for diabetes drug Onglyza</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/study-no-benefits-diabetes-drug-151601536.html</link><description></description><guid isPermaLink="false">yahoo_finance/3305206186</guid><pubDate>Wed, 19 Jun 2013 15:16:01 GMT</pubDate></item><item><title>AstraZeneca, Bristol diabetes drug disappoints in key test</title><link>http://us.rd.yahoo.com/finance/external/reuters/rss/SIG=12m283k6c/*http://www.reuters.com/article/2013/06/19/astrazeneca-diabetes-idUSL5N0EV0FO20130619?type=companyNews&amp;feedType=RSS&amp;feedName=companyNews&amp;rpc=43</link><description></description><guid isPermaLink="false">yahoo_finance/3150952386</guid><pubDate>Wed, 19 Jun 2013 06:55:04 GMT</pubDate></item><item><title>AstraZeneca, Bristol diabetes drug fails to show heart benefit</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://uk.finance.yahoo.com/news/astrazeneca-bristol-diabetes-drug-fails-061521360.html</link><description></description><guid isPermaLink="false">yahoo_finance/431931495</guid><pubDate>Wed, 19 Jun 2013 06:15:21 GMT</pubDate></item><item><title>AstraZeneca, Bristol diabetes drug fails to show heart benefit</title><link>http://us.rd.yahoo.com/finance/external/reuters/rss/SIG=12l2g4oic/*http://www.reuters.com/article/2013/06/19/astrazeneca-diabetes-idUSWLB003L420130619?feedType=RSS&amp;feedName=rbssHealthcareNews&amp;rpc=43</link><description></description><guid isPermaLink="false">yahoo_finance/1697840606</guid><pubDate>Wed, 19 Jun 2013 06:15:21 GMT</pubDate></item><item><title>AstraZeneca turnaround is 3-4 year journey, says CEO</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://uk.finance.yahoo.com/news/astrazeneca-turnaround-3-4-journey-164643187.html</link><description></description><guid isPermaLink="false">yahoo_finance/2468767501</guid><pubDate>Tue, 18 Jun 2013 16:46:43 GMT</pubDate></item><item><title>AstraZeneca turnaround is 3-4 year journey - CEO</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/astrazeneca-turnaround-3-4-journey-161822207.html</link><description></description><guid isPermaLink="false">yahoo_finance/3911506392</guid><pubDate>Tue, 18 Jun 2013 16:18:22 GMT</pubDate></item><item><title>AstraZeneca turnaround is 3-4 year journey, says CEO</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://uk.finance.yahoo.com/news/astrazeneca-turnaround-3-4-journey-161630862.html</link><description></description><guid isPermaLink="false">yahoo_finance/2290659518</guid><pubDate>Tue, 18 Jun 2013 16:16:30 GMT</pubDate></item><item><title>AstraZeneca picks site for new global home in Cambridge</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://uk.finance.yahoo.com/news/astrazeneca-picks-global-home-cambridge-083417667.html</link><description></description><guid isPermaLink="false">yahoo_finance/3924965886</guid><pubDate>Tue, 18 Jun 2013 09:25:22 GMT</pubDate></item><item><title>AstraZeneca picks site for new global home in Cambridge</title><link>http://us.rd.yahoo.com/finance/external/reuters/rss/SIG=12nrqc3v8/*http://www.reuters.com/article/2013/06/18/astrazeneca-cambridge-idUSL5N0EU0OC20130618?feedType=RSS&amp;feedName=rbssHealthcareNews&amp;rpc=43</link><description></description><guid isPermaLink="false">yahoo_finance/1930032617</guid><pubDate>Tue, 18 Jun 2013 08:34:17 GMT</pubDate></item><item><title>AstraZeneca picks its new home in Cambridge next to top hospital</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://uk.finance.yahoo.com/news/astrazeneca-picks-home-cambridge-next-070643561.html</link><description></description><guid isPermaLink="false">yahoo_finance/1707881934</guid><pubDate>Tue, 18 Jun 2013 07:06:43 GMT</pubDate></item><item><title>AstraZeneca picks its new home in Cambridge next to top hospital</title><link>http://us.rd.yahoo.com/finance/external/reuters/rss/SIG=12n5kdlom/*http://www.reuters.com/article/2013/06/18/astrazeneca-cambridge-idUSL5N0EU0LQ20130618?feedType=RSS&amp;feedName=rbssHealthcareNews&amp;rpc=43</link><description></description><guid isPermaLink="false">yahoo_finance/2781539235</guid><pubDate>Tue, 18 Jun 2013 07:06:43 GMT</pubDate></item><item><title>O&apos;Shaughnessy Says Market Trying to Second-Guess Fed (Audio)</title><link>http://us.rd.yahoo.com/finance/external/bloomberg/rss/SIG=13bjft4ln/*http://www.bloomberg.com/news/2013-06-17/o-shaughnessy-says-market-trying-to-second-guess-fed-audio-.html?cmpid=yhoo</link><description></description><guid isPermaLink="false">yahoo_finance/17928202</guid><pubDate>Mon, 17 Jun 2013 12:07:06 GMT</pubDate></item><item><title>BRIEF-AstraZeneca&apos;s MedImmune, NGM Biopharmaceuticals in deal to develop therapies for diabetes and obesity</title><link>http://us.rd.yahoo.com/finance/external/reuters/rss/SIG=12i8plemg/*http://www.reuters.com/article/2013/06/17/astrazeneca-brief-idUSWLB003JP20130617?feedType=RSS&amp;feedName=rbssHealthcareNews&amp;rpc=43</link><description></description><guid isPermaLink="false">yahoo_finance/3590610071</guid><pubDate>Mon, 17 Jun 2013 07:20:12 GMT</pubDate></item><item><title>AstraZeneca: MedImmune, AstraZeneca’s Biologics Arm, and NGM Biopharmaceuticals Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/astrazeneca-medimmune-astrazeneca-biologics-arm-071900714.html</link><description>[Business Wire] - Regulatory News:</description><guid isPermaLink="false">yahoo_finance/3509667022</guid><pubDate>Mon, 17 Jun 2013 07:19:00 GMT</pubDate></item><item><title>&apos;Shareholder spring&apos; reaches small UK businesses</title><link>http://us.rd.yahoo.com/finance/external/ft/rss/SIG=1295cs0ep/*http://www.ft.com/cms/s/45064ace-d37f-11e2-95d4-00144feab7de,s01=1.html</link><description>[at Financial Times] - The shareholder spring has reached small companies, with rising numbers of investors opposing their executive pay plans, according to KPMG, the financial services firm. This year, 20 per cent of small ...</description><guid isPermaLink="false">yahoo_finance/2228212804</guid><pubDate>Sun, 16 Jun 2013 23:52:47 GMT</pubDate></item><item><title>The Stock Picker&apos;s Guide to AstraZeneca</title><link>http://us.rd.yahoo.com/finance/external/mfool/rss/SIG=12uv821a5/*http://www.fool.com/investing/general/2013/06/13/the-stock-pickers-guide-to-astrazeneca.aspx?source=eogyholnk0000001</link><description></description><guid isPermaLink="false">yahoo_finance/1625308918</guid><pubDate>Fri, 14 Jun 2013 02:38:48 GMT</pubDate></item><item><title>AstraZeneca taps outside experts to screen cancer compounds</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://uk.finance.yahoo.com/news/astrazeneca-taps-outside-experts-screen-230100818.html</link><description></description><guid isPermaLink="false">yahoo_finance/3109772461</guid><pubDate>Thu, 13 Jun 2013 23:01:00 GMT</pubDate></item></channel></rss>